Background: It is unknown whether bepridil improves cardiovascular events in atrial fibrillation (AF) patients, so this study evaluated the clinical outcome in paroxysmal or persistent AF patients receiving bepridil.
trial fibrillation (AF) is the most clinically prevalent tachyarrhythmia, and the incidence of AF increases with advancing age. 1,2 AF occurs in patients with a variety of cardiovascular diseases, as well as in those without structural heart disease. The development of AF results in worsening hemodynamics in patients with heart failure or left ventricular (LV) hypertrophy, causing an uncontrolled heart rate with shortened filling time and the provocation of tachycardiomyopathy. The absence of the atrial kick and an irregular ventricular rhythm leads to a decrease in cardiac output. 3 AF is a potential risk factor for stroke, heart failure and death, 4-6 and it impairs quality of life. 7 The therapeutic goal for AF patients is reducing symptoms and preventing the severe complications associated with AF. 8 In the past, most studies assessing the efficacy of antiarrhythmic drugs have focused primarily on the incidence of conversion to sinus rhythm or the prevention of AF, rather than on more global endpoints. 9 However, it remains unclear whether using antiarrhythmic drugs to maintain sinus rhythm is linked to improved clinical outcomes in AF patients. Recently, AF treatment assessment has tended toward evaluating clinical outcomes, including mortality and cardiovascular morbidity, or quality of life since achieving rhythm. To date, there have been no randomized clinical trials comparing rate vs. rhythm control that indicate that rhythm control improve mortality and cardiovascular events. 10- 13 Interestingly, a post-hoc analysis of the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) study suggested that antiarrhythmic drugs are not associated with improved survival because the benefits of sinus rhythm are offset by the drugs' adverse effects. 14 It was concluded that antiarrhythmic drugs have modest effects on restoring and maintaining sinus rhythm in AF and have adverse pro-arrhythmic and extracardiac side effects. The decision to use antiarrhythmic drugs should be based on safety rather than efficacy considerations, such as the maintenance of sinus rhythm.
8,9 Bepridil and Outcome in AF Patients
Bepridil is classified as a calcium-channel blocker and has been used as an antianginal drug in Europe and North America. 15 Bepridil produces a lidocaine-like fast kinetic block of the inward sodium current, blockade of several outward potassium currents and inhibition of sodium-calcium exchange. 15, 16 In Japan, bepridil is used as an antiarrhythmic drug because its unique electrophysiological properties make it behave like class I, class III and class IV antiarrhythmic drugs. Previous reports have shown the efficacy of bepridil in AF patients who were refractory to class I antiarrhythmic drugs. 17-20 Additionally, many clinical studies, including retrospective and prospective evaluations, have shown bepridil's efficacy in converting persistent AF to sinus rhythm. 17,19-24 However, bepridil has serious adverse effects, such as sudden cardiac death, torsade de pointes (Tdp) with QT prolongation and excessive bradyarrhythmia. 24, 25 To date, there have been few reports concerning outcome, including cardiovascular events and safety issues, in AF patients during long-term bepridil therapy. Bepridil has complex pharmacokinetic properties, 26,27 and the optimal safe dose in AF patients has not yet been fully determined. The aim of this study was to evaluate the clinical outcome of patients with paroxysmal or persistent AF who received bepridil.
Methods

Subjects
We conducted a cohort study of 284 consecutive patients who received bepridil for paroxysmal or persistent AF at Tokyo Women's Medical University Hospital between February 1988 and April 2010. Among them, 231 patients (81%) had received class I or class III antiarrhythmic drugs prior to bepridil therapy, and 220 patients were switched to bepridil because class I and class III antiarrhythmic drugs failed to prevent AF recurrence or restore sinus rhythm. An additional, 11 patients were switched from amiodarone to bepridil because of the pulmonary toxicity of amiodarone. The remaining 53 patients received bepridil as a first-line antiarrhythmic drug. A total of 30 patients (11%) received combined therapy with bepridil and a class I antiarrhythmic drug (Figure 1) . The protocol was approved by the Institutional Review Board of Tokyo Women's Medical University.
Drug Dosing
Patients were given oral bepridil at a dose of 100-200 mg daily. In the case of combination therapy with another antiarrhythmic drug, patients were initially given 50 mg daily. The maintenance dose of 50-200 mg daily was adjusted, and the efficacy and side effects of bepridil were monitored.
Among the 30 patients who received combination therapy with bepridil and a class I antiarrhythmic drug, 6 were prescribed 50 mg of bepridil daily, 13 patients were prescribed 100 mg daily, 4 patients were prescribed 150 mg daily and 7 patients were prescribed 200 mg daily.
Classification of AF
Paroxysmal AF is characterized by recurrent episodes alternating with sinus rhythm. Episodes that spontaneously reversed within 7 days without antiarrhythmic drug therapy or electrical cardioversion were classified as paroxysmal, and those that either lasted longer than 7 days or required pharmacological or electrical cardioversion for termination were classified as persistent. If sinus rhythm could not be sustained despite these treatments or if the patient and physician decided to allow AF to continue without further efforts to restore sinus rhythm, the case was classified as permanent AF; 8,28 that is, the term 'permanent AF' was an expression of the patient's intent rather than a description of the pathophysiology.
Definition of Structural Heart Disease
Structural heart disease consisted of the following apparent cardiac disorders: LV systolic dysfunction and/or marked LV dilatation unless secondary to severe valve regurgitation; LV hypertrophy; coronary artery disease; right heart disease with right ventricular dilation of at least moderate severity; moderate or severe tricuspid regurgitation or pulmonary hypertension; left-sided valvular disease; and congenital heart disease. Coronary artery disease was defined as positive stress test findings, coronary angiography demonstrating at least 75% stenosis or coronary spastic angina documented by acetylcholine provocation test, a history of prior myocardial infarction (MI), or a history of revascularization procedures. Valvular and congenital heart diseases were defined according to the angiographic, hemodynamic or echocardiographic findings or a history of valvular or congenital cardiac surgery. Atrial or mitral regurgitation was defined as valvular disease when we identified greater than moderate regurgitation on color flow Doppler echocardiography. Nonischemic cardiomyopathies were defined as ventricular myocardial abnormalities in the absence of coronary artery disease or valvular, pericardial or congenital heart disease.
Follow-up
Follow-up data were obtained at routine visits to our institution (every 1-3 months). Patients were followed until the end of the follow-up period (August 31, 2010), until death, until bepridil was discontinued, or until they were lost to followup. Information about deceased patients was obtained from medical records, family members, patients' general practitioners and the hospitals to which they had been admitted.
Baseline 12-lead ECG, chest X-ray, echocardiography, and renal and liver function tests were performed for most patients before bepridil therapy. 12-lead ECG was performed at each routine visit and several times during therapy. The 12-lead ECGs were recorded at standard gain (10 mm/mV) and speed (25 mm/s). Heart rate, QRS duration, QT and corrected QT (QTc) intervals were measured by 2 independent investigators (A.S. and M.N.). The QT interval was measured from the onset of the QRS interval to the end of the T wave in all the leads for which the end of the T wave could be clearly defined. The QTc value was measured using Bazett's formula. After May 2007, blood samples for plasma drug concentrations were also drawn if patients gave informed consent. The plasma bepridil concentration was measured by high-pressure liquid chromatography assay.
Endpoints
The primary endpoint was the time to first cardiovascular event and was a composite of the following: cardiovascular death, non-fatal MI, hospitalization for unstable angina, hospitalization for heart failure, hospitalization for stroke, hospitalization for other cardiovascular disease, documented Tdp, sustained ventricular tachycardia or fibrillation, and syncope/ presyncope, which were considered because they are potential symptoms of Tdp. Cardiovascular death was defined as death due to myocardial or cerebral infarction or documented sudden cardiac death. Unstable angina was defined according to the Braunwald criteria. 29 Heart failure was defined on the basis of symptoms, such as dyspnea, clinical signs, such as rales or ankle edema, and the need for treatment with diuretics, vasodilators, or inotropics. Stroke was defined as a new focal neurological deficit of vascular origin lasting more than 24 h. Stroke was further classified as the result of intracranial hemorrhage, ischemia (if results of computed tomography or magnetic resonance imaging were available), or uncertain cause. Other cardiovascular events included peripheral artery diseases, dissecting aneurysm of the aorta, and aortic aneurysm rupture. The main secondary endpoint was a composite of the following: total mortality, symptomatic cerebral infarction, systemic embolism, major bleeding, or hospitalization for heart failure, which was used as the primary outcome minus physical/psychological disability (hard endpoint) in the J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study. 13 Another secondary endpoint was the time to diagnosis of permanent AF. 
Side Effects
We observed bepridil-related cardiac adverse events, including sudden arrhythmic death, ventricular tachyarrhythmia (including Tdp), excessive QTc prolongation (>0.50 s), excessive bradycardia requiring the discontinuation of bepridil and/ or additional therapy. Extracardiac adverse events, such as gastrointestinal symptoms and liver dysfunction (alanine aminotransferase ≥3 × normal and/or alkaline phosphatase >nor-mal), were also observed.
Statistical Analysis
Summary data are presented either as mean ± SD or number of patients. Categorical variables were subjected to chi-square analysis. Time to first occurrence of events was analyzed using the Kaplan-Meier method with the log-rank test. P<0.05 was considered significant. Data analyses were performed with SPSS statistical software (version 11.01, SPSS Inc, Chicago, IL, USA).
Results
Patients' Characteristics
The patients' baseline characteristics are shown in Table 1 .
The mean age when bepridil was started was 59±13 years, and 25% of the patients treated were women. A total of 21 patients (7%) had persistent AF; 135 patients (48%) had structural heart diseases; 63 (22%) had a history of congestive heart failure; 80 (28%) had hypertension; 39 (14%) had diabetes. Regarding concomitant medications at baseline, 126 patients (44%) had taken angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, 143 patients (50%) had taken β-blockers, and 38 patients (13%) had taken a statin. The proportion of patients with a CHADS2 score of 0, 1 or ≥2 was 44%, 31% and 25%, respectively. 152 patients (54%) used warfarin, and 108 (38%) used aspirin. We lost 8 patients to follow-up; the remaining 276 patients (97%) were followed completely. Bepridil was discontinued because of ineffective prevention of AF (86 patients), progression to permanent AF (30 patients), side effects (17 patients) or the patient's own decision (1 patient). The median follow-up period was 17 months (range 4-157 months).
Endpoints
The Kaplan-Meier curve for the primary endpoint is shown in Figure 2 . Each primary endpoint is shown in in patients with structural heart disease compared with those without. The Kaplan-Meier curve for the main secondary outcome is shown in Figure 3 . The cumulative rate for the main secondary endpoint at 1, 3, and 5 years was 9.7%, 18.2%, and 29.6%, respectively. A trend toward higher rates for the main secondary endpoint was observed in patients with structural heart disease compared with those without. The causes of death were sudden death (1 patient), heart failure (5 patients), dissection of aorta (1 patient) and non-cardiac causes (7 patients). Permanent AF was the diagnosis in 39 patients during bepridil therapy. The cumulative rate for the time to permanent AF diagnosis at 1, 3, and 5 years during bepridil therapy was 8.3%, 12.1%, and 23.5%, respectively (Figure 4) .
Adverse Events
The numbers of patients who experienced adverse events according to their maintenance dose of bepridil are shown in Table 3 . Regarding serious adverse events, sudden death occurred in 1 patient who had a prior MI (200 mg daily), and Tdp occurred in 2 patients without structural heart disease (both 200 mg daily). The rate of QTc prolongation (>0.50 s) was highest (11%) in patients taking 200 mg bepridil. A total of 17 patients (6%) discontinued bepridil therapy due to its side effects, which included the following: Tdp (2 patients), QT prolongation (3 patients), sinus bradycardia (1 patient), and non-cardiac causes such as gastrointestinal symptoms (4 patients), liver dysfunction (4 patients) and neurological symptoms (3 patients).
Blood Concentration
The distribution of plasma bepridil concentrations according to the maintenance dose (77 patients, 439 points) is shown in Figure 5 . With dosages of ≤100 mg daily, a dose-dependent effect was observed. However, a high variation in plasma concentration was found, and a dose-dependent effect was not always observed with dosages ≥100 mg daily. Excessive QTc prolongation (>0.50 s) was found in plasma concentrations >800 ng/ml.
Discussion
Our study revealed the following: (1) a probability of cardiovascular events of 10.1% at 5 years in AF patients receiving bepridil; (2) a total of 75.7% of patients receiving bepridil had paroxysmal or persistent AF that was refractory to class I antiarrhythmic drugs; (3) a probability of progression to permanent AF of 23.5% at 5 years in paroxysmal or persistent AF patients receiving bepridil; (4) adverse events, especially Tdp, seemed to occur in a dose-dependent manner; (5) high variation in plasma concentrations even among patients taking the same dose of bepridil, and excessive QTc prolongation occurred mostly at concentrations >800 ng/ml. In our study, we evaluated clinical outcome (AF-related, complicated heart disease-related and bepridil-related) as the primary endpoint and general outcome in AF patients (for comparison with the previous AF outcome study in Japan) as the main secondary endpoint. On average, our subjects were 10 years younger than the subjects in previous AF mortality studies, so the mortality and cardiovascular event rates were low. 10,11 However, the overall rate of the main secondary outcome, which was the hard endpoint in the J-RHYTHM study, was higher than in the J-RHYTHM study, in which the subjects were older (mean age: 65 years). 13 In particular, both the incidence of death due to worsening heart failure and of non-cardiac death was high in our study. Compared to subjects in the J-RHYTHM study, our subjects had a similar distribution of CHADS2 scores, but a higher proportion of patients in our study had structural heart disease or a history of congestive heart failure. A trend toward a higher rate of cardiovascular events in patients with structural heart disease compared to patients without structural heart disease was observed. Nevertheless, because the proportion of warfarin use among our patients was similar to that in the J-RHYTHM study, the incidence of stroke was identical (our study: 2.1%; J-RHYTHM study: 2.1% 13 ). Although the clinical backgrounds of the patients contributed to the outcomes, bepridil may not be helpful in improving the outcomes of AF patients with structural heart disease. The Canadian Registry of Atrial Fibrillation study consisted of 757 patients with paroxysmal AF (mean age: 61 years; ≈40% with structural heart disease). This study showed that the probability of progression to permanent AF was 8.6% and 24.7% at 1 and 5 years, respectively. 31 Moreover, another study with a small sample number reported that among patients with drug-intolerant or drug-refractory paroxysmal AF on long-term antiarrhythmic drug therapy, the probability of progression to permanent AF was more than 30% at 5 years. 32 Factors such as age and structural or substrate abnormalities contribute to the progression to a permanent form of AF. 31, 33 The rate of progression to permanent AF was not as high among our subjects (mean age: 59 years; 48% with structural heart disease) as in previous studies, even though our subjects were mostly AF patients who did not respond to class I antiarrhythmic drugs. Bepridil is an antiarrhythmic drug with multiple therapeutic actions, 15, 16 and it has been found to be effective in converting AF to sinus rhythm and maintaining sinus rhythm in persistent AF or AF that is refractory to class I antiarrhythmic drugs. 17- 24 However, the safety of bepridil is a major problem, especially with respect to Tdp associated with QT prolongation. 15-25, 34 In our study, sudden death and Tdp occurred in patients who took 200 mg daily. Moreover, 17 patients (6%) discontinued bepridil therapy due to its side effects, including QT prolongation, which seem to occur in a dose-dependent manner. Hypokalemia, bradycardia, heart failure, LV hypertrophy and high drug concentrations are recognized as risk factors for Tdp in the presence of a culprit drug. 35 In practice, as long as bepridil is used to manage AF, physicians must carefully monitor these factors, and bepridil should be avoided in AF patients with heart failure or LV hypertrophy.
We also monitored the blood concentration of bepridil, starting in May 2007. Bepridil has complex pharmacokinetic properties: low systemic bioavailability (approximately 60%), a large volume of distribution (8 L/kg), and a long elimination half-life (1-2 days) with a single oral dose and even longer at steady state. 26, 27 Therefore, large interindividual differences in blood concentrations were observed, even among patients taking the same dose. Sugi et al reported that the bepridil blood concentration was 270±140 ng/ml in patients receiving 100 mg daily, 530±520 ng/ml in patients receiving 150 mg daily and 680±360 ng/ml in patients receiving 200 mg daily. Additionally, the proportion of patients whose AF was prevented by taking bepridil (vs. those who continued to experience AF while taking bepridil) was highest among patients receiving 200 mg daily with blood concentrations >600 ng/ml. 36 In contrast, Kurita et al reported that most of the patients who developed Tdp during bepridil therapy had taken 200 mg daily and had blood concentrations >500 ng/ml. 37 This demonstrates that there is considerable overlap between the effective dose/ concentration and toxicity with bepridil therapy. In our results, excessive QTc prolongation occurred in patients with plasma bepridil concentrations >800 ng/ml, and blood concentrations of at least 1,000 ng/ml might be a risk factor for developing Tdp. After we began monitoring blood concentrations, the mean maintenance dose of bepridil was decreased from 141±46 mg daily (February 1988 
Study Limitations
First, this study was a retrospective observational study conducted in a single center, so treatment bias existed. We could not evaluate the relationship between AF recurrence and outcome. It is difficult to obtain the exact time to first recurrence or the frequency of AF recurrence from a patient's symptoms and routine ECGs in clinical practice. Second, the clinical characteristics of the subjects varied, and the number of subjects was small. Therefore, subgroup analysis was not feasible.
Conclusions
Bepridil is mostly used as a second-line therapy for AF patients who are refractory to class I or class III antiarrhythmic drugs. However, bepridil might not improve the clinical outcomes in these AF patients, especially those with structural heart disease. Moreover, its severe adverse events, including QT prolongation and Tdp, occur in a dose-and concentrationdependent manner. Monitoring the blood bepridil concentration and low-dose treatment regimens may help decrease adverse events.
